An epidemiOlogy study to deteRmine the prevalence of EGFR (Epidermal growth factor receptor) muTations in RUSsian patients with advanced NSCLC (Non-Small Cell Lung Cancer).

Trial Identifier: D133FR00101
Sponsor: AstraZeneca
NCTID:: NCT02321046
Start Date: September 2015
Primary Completion Date: June 2019
Study Completion Date: June 2019
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Russia, Russia Arkhangelsk, Russia, Russia
Russia, Russia Barnaul, Russia, Russia
Russia, Russia Chelyabinsk, Russia, Russia
Russia, Russia Irkutsk, Russia, Russia
Russia, Russia Kemerovo, Russia, Russia
Russia, Russia Khabarovsk, Russia, Russia
Russia, Russia Khanti-Manskiysk, Russia, Russia
Russia, Russia Kirov, Russia, Russia
Russia, Russia Krasnodar, Russia, Russia
Russia, Russia Krasnoyarsk, Russia, Russia
Russia, Russia Moscow, Russia, Russia
Russia, Russia Nizhniy Novgorod, Russia, Russia
Russia, Russia Novisibirsk, Russia, Russia
Russia, Russia Novosibirsk, Russia, Russia
Russia, Russia Obninsk, Russia, Russia
Russia, Russia Omsk, Russia, Russia
Russia, Russia Orenburg, Russia, Russia
Russia, Russia Rostov-on-Don, Russia, Russia
Russia, Russia Saint-Petersburg, Russia, Russia
Russia, Russia Samara, Russia, Russia
Russia, Russia Tambov, Russia, Russia
Russia, Russia Tomsk, Russia, Russia
Russia, Russia Ufa, Russia, Russia
Russia, Russia Vladivostok, Russia, Russia
Russia, Russia Volgograd, Russia, Russia
Russia, Russia Yuzhno-Sakhalinsk, Russia, Russia